Grass Pollen Allergy - Pipeline Review, H2 2018

Global Markets Direct’s, ‘Grass Pollen Allergy - Pipeline Review, H2 2018’, provides an overview of the Grass Pollen Allergy pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Grass Pollen Allergy, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Grass Pollen Allergy and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Grass Pollen Allergy

- The report reviews pipeline therapeutics for Grass Pollen Allergy by companies and universities/research institutes based on information derived from company and industry-specific sources

- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

- The report reviews key players involved Grass Pollen Allergy therapeutics and enlists all their major and minor projects

- The report assesses Grass Pollen Allergy therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

- The report summarizes all the dormant and discontinued pipeline projects

- The report reviews latest news related to pipeline therapeutics for Grass Pollen Allergy

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of therapeutics under development for Grass Pollen Allergy

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Grass Pollen Allergy pipeline depth and focus of Indication therapeutics

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

ALK-Abello AS

Allergy Therapeutics Plc

ASIT Biotech SA

Biomay AG

HAL Allergy BV

Regeneron Pharmaceuticals Inc

ALK-Abello AS

Allergy Therapeutics Plc

ASIT Biotech SA

Biomay AG

HAL Allergy BV

Regeneron Pharmaceuticals Inc

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Grass Pollen Allergy – Overview

Grass Pollen Allergy – Therapeutics ...

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Grass Pollen Allergy – Overview

Grass Pollen Allergy – Therapeutics Development

Pipeline Overview

Pipeline by Companies

Products under Development by Companies

Grass Pollen Allergy – Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Grass Pollen Allergy – Companies Involved in Therapeutics Development

ALK-Abello AS

Allergy Therapeutics Plc

ASIT Biotech SA

Biomay AG

HAL Allergy BV

Regeneron Pharmaceuticals Inc

Grass Pollen Allergy – Drug Profiles

Allergen for Pollen Grass Allergy Induced Allergic Rhinitis and Rhinoconjunctivitis – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BM-32 – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

dupilumab – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

gp-ASIT – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Pollinex Quattro Grass – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

standardized grass pollen [timothy (Phleum pratense)] allergen extract – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Vaccine 1 for Grass Pollen Allergy – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Vaccine for Grass Pollen Allergy – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Grass Pollen Allergy – Dormant Projects

Grass Pollen Allergy – Discontinued Products

Grass Pollen Allergy – Product Development Milestones

Featured News & Press Releases

Jun 25, 2018: Allergy Therapeutics announces publication of data demonstrating long-lasting efficacy of Pollinex Quattro Grass vaccine in Immunotherapy

May 21, 2018: Allergy Therapeutics announces positive top-line results from its Grass MATA MPL Phase II dose ranging study

Mar 12, 2018: The quality of the results obtained in the phase III clinical study with gp-ASIT+ confirmed by the publication in the prestigious scientific journal ALLERGY

Feb 05, 2018: Landmark clinical study with grass pollen vaccine BM32 published

Jan 11, 2018: ASIT Biotech is Publishing a New Article on the Clinical Result of gp-ASIT+ in the Prestigious Science Journal ALLERGY

Dec 14, 2017: ASIT biotech reviews the efficacy results of gp-ASIT+ observed during the phase III trial completed in 2016

Dec 06, 2017: ASIT biotech significantly moves forward in the preparation of the clinical development plan of gp-ASIT+ in the US

Jul 03, 2017: ASIT biotech Presented the Immunogenicity Data of the gp-ASIT+ Phase III Clinical Study for the Treatment of Grass Pollen Rhinitis at EAACI 2017

Feb 27, 2017: ASIT biotech Will Publish the Results of the Phase 3 Clinical Trial with Its gp-ASIT+ Product Candidate for Treating Grass Pollen Rhinitis on 28 February, 2017

Jan 26, 2017: Biomay AG Reports Positive Results From A Second Phase IIb Trial With The Innovative 3rd Generation Grass Pollen Allergy Vaccine BM32

Dec 05, 2016: ASIT+ technology’s benefits in treating grass pollen rhinitis presented during a scientific session at Medical Research Council & Asthma UK Centre in London

Nov 14, 2016: ASIT biotech takes important steps in US clinical development of gp-ASIT+, its lead drug candidate for grass pollen rhinitis

Oct 05, 2016: ASIT biotech announces the last patient last visit in the Phase III clinical study with its first product candidate gp-ASIT+

Sep 08, 2016: Grass pollen allergy vaccine also effective against hepatitis B

Jun 27, 2016: Allergy Therapeutics announces findings from mEEC dose range finding study G204

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

List of Tables

Number of Products under Development for Grass Pollen Allergy, H2 2018

Number of Products under Development by Companies, H2 2018

Products under ...

List of Tables

Number of Products under Development for Grass Pollen Allergy, H2 2018

Number of Products under Development by Companies, H2 2018

Products under Development by Companies, H2 2018

Number of Products by Stage and Target, H2 2018

Number of Products by Stage and Mechanism of Action, H2 2018

Number of Products by Stage and Route of Administration, H2 2018

Number of Products by Stage and Molecule Type, H2 2018

Grass Pollen Allergy – Pipeline by ALK-Abello AS, H2 2018

Grass Pollen Allergy – Pipeline by Allergy Therapeutics Plc, H2 2018

Grass Pollen Allergy – Pipeline by ASIT Biotech SA, H2 2018

Grass Pollen Allergy – Pipeline by Biomay AG, H2 2018

Grass Pollen Allergy – Pipeline by HAL Allergy BV, H2 2018

Grass Pollen Allergy – Pipeline by Regeneron Pharmaceuticals Inc, H2 2018

Grass Pollen Allergy – Dormant Projects, H2 2018

Grass Pollen Allergy – Discontinued Products, H2 2018

List of Figures

List of Figures

Number of Products under Development for Grass Pollen Allergy, H2 2018

Number of Products under Development by Companies, H2 2018

Number of ...

List of Figures

Number of Products under Development for Grass Pollen Allergy, H2 2018

Number of Products under Development by Companies, H2 2018

Number of Products by Routes of Administration, H2 2018

Number of Products by Stage and Routes of Administration, H2 2018

Number of Products by Molecule Types, H2 2018

Number of Products by Stage and Molecule Types, H2 2018

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports